Biolog-id uses RFID technology to transform lifesaving and sensitive therapeutic products into connected devices, enhancing the management and traceability of products used in medical treatments.

Biolog-id

Paragon ID SA provides identification solutions worldwide. It offers access control, brand protection, contactless ticketing, label, customer relationship management, magnetic and mobile ticketing, near field communication, operation maintenance, RFID technology, secure application module, smartcard kiosk, stock management, timed use ticketing, transport item tracking, and secure service solutions. The company also provides contactless and dual interface smart cards, identification documents, metal bank cards, passport E-covers, RFID labels and tags, and eTrust that transforms secure paper-based products into intelligent documents, as well as various terminals, including couplers, readers, and accessories. It serves various clients in automotive, aviation, gaming, health, higher education, logistics, luxury products, manufacturing, mass transit and transport, mobility, parking, payment, pharmaceutical, retail, secure ID, and sport and leisure industries. The company was incorporated in 2019 and is headquartered in Mougins, France. Paragon ID SA is a subsidiary of Paragon Group Limited.

Paragon ID SA

Biolog-id | 4,531 followers on LinkedIn. The smart healthcare solution for the management and traceability of sensitive health products. | Every public health organization is faced with the challenge of placing patients at the heart of their work and satisfying the demand for results.

Every year and all over the world, 108 million blood donations are collected, and almost 20 million new cases of cancer diagnosed. Given the growing and aging population with changing lifestyles, the need for blood and chemotherapy products will only continue to increase.

Ashraf Elsisy

Chief Operating Officer at Biolog-id

Bruno Chappert

Director, Data & Analytics at Biolog-id

David Jean-Baptiste, MS MIT

Regional Sales Manager at Biolog-id

Annalisa Starace

Biolog-id est à la recherche de son futur talent ! Toutes les informations se trouvent dans la fiche de poste ci-dessous. #customercare #santé #france #transfusion #oncologie

Biolog-id est fier de partager l’interview réalisée par le site d’information de la BPI avec le CEO de l’entreprise, qui décrit l’aventure de notre scale-up depuis bientôt 20 ans à travers ses défis quotidiens et son rayonnement à l’international. #transfusion #oncologie #santéconnectée #RFID #bloodbank #bloodmanagement #bloodcenter #ISBT #AABB

Biolog-id was pleased to attend the Global Health Exhibition from 21 to 23 October in Riyadh, Saudi. This year, through a presence on Algosaibi booth, it was a great opportunity to meet with some key people involved in transfusion and present our latest developments. #transfusion #innovation #healthcare #KSA #congress

SAVE THE DATE | #GERPAC2024 📅 Biolog-id sera présent au congrès GERPAC du 2 au 4 octobre à Hyères, pour vous présenter la solution C-LOG®. Nous serons ravis de vous accueillir au stand n°8 pour une démonstration. Au plaisir de tous vous y voir ! #congrès #oncologie #gerpac #santéconnectée

SAVE THE DATE | #TRANSMEDCON 2024 📅 Biolog-id is ready for TRANSMEDCON 2024 Mahabalipuram in India! We are delighted to attend the Annual National Conference of Indian Society of Transfusion Medicine and share with you the latest developments in our Blood Transfusion solution. Come and visit us at booth n°24 & 38. We can’t wait to see you! #congress #bloodtransfusion #healthcare #healthconnected

Biolog-id was at International Society of Blood Transfusion (ISBT) in Barcelona! This was an opportunity to see our customers, who continue to show increasing interest in the Biolog transfusion solution. It was also a pleasure to meet many prospects, who asked for demonstrations of the Smart Access Kit, Biolog-id's latest innovation. #transfusion #innovation #healthcare #connectedhealth #ISBT #internationalcongress

SAVE THE DATE | #ISBT 📅 Biolog-id is ready for International Society of Blood Transfusion (ISBT) 2024 in Barcelona! We are happy to attend the ISBT congress and share with you the latest developments in our Blood Transfusion solution. Come and visit us at booth N°A24. We can’t wait to meeting you! #congress #ISBT #bloodtransfusion #connectedhealth

Metric
Company Name	Biolog-id	Paragon ID SA
Symbol		PID
MSH ID	COM:BIOLOG-ID	COM:PARAGON-ID
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Technology
Industry	Medical Devices	Semiconductors
Country	FR	FR
Stage	Venture Round
Employee Count		856
Website	biolog-id.com	paragon-id.com
LinkedIn	biolog-id	paragon-identification
Founders

Metric
Market Cap		79.68M
Enterprise Value
Monthly Web Traffic	671
Web Traffic Growth	2.31
Valuation
Raised Capital	25M

Metric
Revenue		202.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit		94.09M
EBITDA		13.56M
Operating Income		4.05M
Net Income		149.98K
EPS		0.08
Diluted EPS		0.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.45
Operating Profit Margin		0.02
EBITDA Margin		0.07
Net Profit Margin		0.00
Return on Equity		0.01
Return on Assets		0.00
Return on Capital Employed		0.05

BIOL

COM:BIOLOG-ID

Biolog-id

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		532.98
P/B Ratio		3.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.39
EV Multiple		0.47

Metric
Days Sales Outstanding
Days Payables Outstanding		111.61
Days Inventory Outstanding		96.31
Operating Cycle		127.84
Cash Conversion Cycle		19.08
Asset Turnover		1.17

Metric
Operating Cash Flow		12.57M
Free Cash Flow		415.10K
Cash Flow to Debt		0.15
Operating Cash Flow/Sales		0.06
Free Cash Flow Yield		0.01

Metric
Cash & Equivalents		6.68M
Accounts Receivable		-456.29K
Inventory		29.41M
Goodwill		65.51M
Debt to Capitalization		0.78
Debt to Assets		0.47
Current Ratio		0.73
Quick Ratio		0.28

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.00
R&D to Revenue
SG&A to Revenue		0.01